AU9617398A - Erythropoietin-mediated neurogenesis - Google Patents

Erythropoietin-mediated neurogenesis

Info

Publication number
AU9617398A
AU9617398A AU96173/98A AU9617398A AU9617398A AU 9617398 A AU9617398 A AU 9617398A AU 96173/98 A AU96173/98 A AU 96173/98A AU 9617398 A AU9617398 A AU 9617398A AU 9617398 A AU9617398 A AU 9617398A
Authority
AU
Australia
Prior art keywords
erythropoietin
neurogenesis
mediated
mediated neurogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU96173/98A
Other languages
English (en)
Inventor
S. Todd Sorokan
Samuel Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurospheres Holdings Ltd
Original Assignee
Neurospheres Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22046528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU9617398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurospheres Holdings Ltd filed Critical Neurospheres Holdings Ltd
Publication of AU9617398A publication Critical patent/AU9617398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU96173/98A 1997-10-24 1998-10-23 Erythropoietin-mediated neurogenesis Abandoned AU9617398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6304097P 1997-10-24 1997-10-24
US60063040 1997-10-24
PCT/CA1998/000991 WO1999021966A1 (en) 1997-10-24 1998-10-23 Erythropoietin-mediated neurogenesis

Publications (1)

Publication Number Publication Date
AU9617398A true AU9617398A (en) 1999-05-17

Family

ID=22046528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU96173/98A Abandoned AU9617398A (en) 1997-10-24 1998-10-23 Erythropoietin-mediated neurogenesis

Country Status (5)

Country Link
US (7) US6165783A (https=)
JP (1) JP2001520878A (https=)
AU (1) AU9617398A (https=)
CA (1) CA2307017C (https=)
WO (1) WO1999021966A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
DE19928210B4 (de) * 1999-06-19 2005-08-18 Neuroprogen Gmbh Leipzig Neuronales Zellmaterial und Verfahren zu dessen Herstellung
JP2003505023A (ja) * 1999-07-16 2003-02-12 プレサイエント ニューロファーマ インコーポレイテッド 細胞治療用細胞の産生および調製の方法
AU3499801A (en) * 2000-02-11 2001-08-20 Schepens Eye Res Inst Isolation and transplantation of retinal stem cells
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
MXPA02011727A (es) * 2000-05-26 2003-10-24 Johnson & Johnson Peptidos neuroprotectores.
JP5053499B2 (ja) * 2000-06-30 2012-10-17 地方独立行政法人東京都健康長寿医療センター 脱髄疾患の予防及び治療薬
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
DK1471871T3 (da) 2001-02-02 2007-09-17 Ortho Mcneil Pharm Inc Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
US7838292B1 (en) 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
AU2002325712C1 (en) * 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
KR100505152B1 (ko) * 2001-09-10 2005-08-03 (주)가이아진 아스코르브산을 이용한 에리트로포이에틴의 생산방법
JP4906231B2 (ja) * 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
WO2003024471A2 (en) * 2001-09-18 2003-03-27 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
EP1471970A4 (en) * 2002-01-14 2006-08-02 Univ Illinois NOVEL MULTIPOTENT STEM CELLS OF MAMMALIAN ORIGIN, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION OF SAID CELLS
WO2003078959A2 (en) * 2002-03-11 2003-09-25 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
WO2003103608A2 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2004011497A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2004075818A2 (en) * 2003-02-26 2004-09-10 Proteosys Ag Stress specific molecular response in neurons
NZ542092A (en) * 2003-03-27 2008-04-30 Janssen Pharmaceutica Nv Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
CN1867678B (zh) * 2003-09-12 2012-10-03 干细胞技术公司 神经集落形成分析
US7546127B2 (en) * 2003-09-26 2009-06-09 Siemens Communications, Inc. System and method for centrally-hosted presence reporting
BRPI0414887A (pt) * 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
EP1550715A1 (de) * 2003-12-30 2005-07-06 Bionethos Holding Gmbh Verfahren zur Regenation von Gewebe
AU2004309083B2 (en) 2003-12-30 2010-11-11 Augustinus Bader Tissue regeneration method
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
WO2005079250A2 (en) * 2004-02-13 2005-09-01 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
AU2006269231A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US7776592B2 (en) * 2005-08-31 2010-08-17 Stc.Unm Human renal stem cells
US7534765B2 (en) 2005-09-27 2009-05-19 Stem Cell Therapeutics Corp. Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin
US20070077200A1 (en) * 2005-09-30 2007-04-05 Baker Clark R Method and system for controlled maintenance of hypoxia for therapeutic or diagnostic purposes
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US8899228B2 (en) 2006-02-08 2014-12-02 Cvac Systems, Inc. Combination pressure therapy for treatment of chronic pain
US20070193578A1 (en) * 2006-02-08 2007-08-23 Cvac Systems, Inc. Combination Pressure Therapy for Treatment of Ischemia & Heart Conditions, Diabetes, Alzheimer's Disease and Cancer
CN101495078B (zh) * 2006-02-08 2013-02-13 Cvac系统有限公司 组合压力疗法
KR20080103108A (ko) * 2006-03-17 2008-11-26 스템 셀 테라퓨틱스 코포레이션 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2081956B1 (en) * 2006-11-13 2013-03-20 Charité - Universitätsmedizin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
EP2124722A4 (en) 2007-02-26 2012-01-04 Cvac Systems Inc COMBINATION PRESSURE THERAPY FOR SERUM FAT, STEROID MIRROR AND STEROIDOGENESIS
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
US8790638B2 (en) * 2009-02-04 2014-07-29 Stemedica Cell Technologies, Inc. Compositions of stem cells and stem cell factors and methods for their use and manufacture
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
CN108588025A (zh) 2012-02-17 2018-09-28 斯格本斯眼科研究所 人视网膜祖细胞的表型谱
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
KR102056447B1 (ko) * 2018-03-16 2019-12-16 (주)메디노 신경줄기세포를 이용한 혈관형성 유도 방법
CN110713982A (zh) * 2019-11-25 2020-01-21 深圳科学之门生物工程有限公司 一种用于神经干细胞快速扩增的培养基

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198404T5 (es) * 1991-07-08 2008-05-01 Neurospheres Holdings Ltd. Celulas progenitoras neurales que responden a factor de crecimiento y que se pueden hacer proliferar in vitro.
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
EP0669973B9 (en) * 1992-10-28 2007-10-10 NeuroSpheres Holdings Ltd. Biological factors and neural stem cells
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
CA2175992C (en) * 1993-11-09 2008-04-01 Samuel Weiss In situ modification and manipulation of stem cells of the central nervous system
FI971956L (fi) * 1994-11-14 1997-07-04 Neurospheres Holdings Ltd Hermosolujen lisääntymisen säännöstely
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis

Also Published As

Publication number Publication date
JP2001520878A (ja) 2001-11-06
US6165783A (en) 2000-12-26
US20060127372A1 (en) 2006-06-15
US20020098585A1 (en) 2002-07-25
CA2307017C (en) 2014-01-28
US20020094571A1 (en) 2002-07-18
US20050026136A1 (en) 2005-02-03
US20010039049A1 (en) 2001-11-08
US20030104619A1 (en) 2003-06-05
US6368854B2 (en) 2002-04-09
WO1999021966A1 (en) 1999-05-06
US6924142B2 (en) 2005-08-02
CA2307017A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU9617398A (en) Erythropoietin-mediated neurogenesis
AU1709299A (en) Mixer-injectors
AU9414098A (en) Ascorbyl-phosphoryl-cholesterol
AU6598798A (en) Resorcinyl-triazines
AU1027499A (en) 32P-polyphosphazene
AU5272198A (en) EMP-charge-eliminator
AU4117497A (en) Micropolarimeter
AU6185898A (en) Clavaspirins
AU8214598A (en) 3-benzylpiperidine
AU7761998A (en) Korrosionsschutzanstrichstoff
AU9183798A (en) Catamaran - bicycle - kayak
AU5391798A (en) Thiamacrolides
AU8991998A (en) Renovative pipeliner
AU5540298A (en) Rockbolts
AU6237398A (en) N-het-substituted glycerophosphoethanolamines
AU7208798A (en) 1-cyano-2-alkylthio-2-arylthioethenes
AU6507298A (en) Renovative pipeliner
AU7780498A (en) Cafetiere
AU8121298A (en) G-seat
AU6060598A (en) Multi-hopper
AUPO975897A0 (en) Remouldable form
AUPO471997A0 (en) Ezy-hang-bracket
AUPO547797A0 (en) Oceancam
AU9168398A (en) Bowgrip
AU1683599A (en) Cyclopeptolides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase